Skip to main
HAE

Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics (HAE) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Haemonetics is a global company with two core business units: Apheresis (Plasma and Blood Center) and MedSurg (Blood Management and Interventional Technologies). The company has been shifting its revenue base towards the MedSurg segment through acquisitions, which is now its largest business segment. With new product launches and potential growth in the Plasma and Hospital businesses, we expect continued profitability and potential for best-in-class margins among MedTech peers. Recent commercial stumbles have led to scrutiny in the Interventional Technologies sub-segment but the company has potential for sustained sales growth through new products and potential M&A.

Bears say

Haemonetics is facing strong competition in the blood center segment, potentially limiting growth potential in this area. Furthermore, the decline in the interventional technologies business and lack of significant growth in the hospital segment raises concerns about the company's future financial performance. With the company's reliance on disposable products and current challenges in sales strategy, the negative outlook for Haemonetics's stock is justified.

Haemonetics (HAE) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Haemonetics (HAE) Forecast

Analysts have given Haemonetics (HAE) a Buy based on their latest research and market trends.

According to 9 analysts, Haemonetics (HAE) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Haemonetics (HAE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.